Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
Part of Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a rare cancer confirmed by biopsy or cell sample.
- You have tried and did not benefit from a PD-1 inhibitor (like pembrolizumab or nivolumab).
- You are 18 years or older and in fairly good health (able to do daily activities with little or no help).
- You have at least one tumor that can be measured on a CT scan.
- Your blood counts and liver, kidney, and clotting functions are within safe ranges.
- You have not received cisplatin or gemcitabine before and had your cancer get worse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and whether it can shrink tumors or slow their growth.
This trial tests a new combination of two investigational drugs, 7MW3711 and JS207, for people with advanced solid tumors that no longer respond to standard treatments. It aims to see if this combination is safe and effective.
This trial tests the drug cisplatin in patients with advanced pancreatic cancer that has a specific DNA repair problem called homologous recombination deficiency (HRD). It may offer a new treatment option for those whose cancer has progressed after at least one prior chemotherapy.
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 inhibitor) as the first treatment for advanced bile duct or gallbladder cancer. It aims to see if this combination works better and to understand how the immune system responds.
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.